Clinical report describes effectiveness and side effects of subcutaneous efgartigimod in generalized myasthenia gravis, highlighting therapy outcomes.
To describe the clinical effectiveness and side effects of subcutaneous efgartigimod use in 3 patients with acetylcholine receptor-positive generalized myasthenia gravis (AChR +ve gMG).
No takes yet. Share an insight, caveat, or question.
King et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: